FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051884642> ?p ?o ?g. }

• W2051884642 endingPage "1478" @default.
• W2051884642 startingPage "1469" @default.
• W2051884642 abstract "In Brief BACKGROUND: Antifibrinolytics are widely used in cardiac surgery to reduce bleeding. Allogeneic blood transfusion, even in primary cardiac operations with low blood loss, is still high. In the present study we evaluated the impact of tranexamic acid compared to aprotinin on the transfusion incidence in cardiac surgical patients with low risk of bleeding. METHODS: This prospective, randomized, double-blind study included 220 patients undergoing primary coronary artery revascularization (coronary artery bypass grafting [CABG]) or aortic valve replacement (AVR). Randomized in blocks of 20, patients received either tranexamic acid (approximately 6 g) or full-dose aprotinin (approximately 5–6 × 106 Kallikrein Inhibiting Units). Transfusion was guided by a strict transfusion algorithm. Molecular markers of hemostasis were determined to assess differences in the mode of action of the two drugs. Primary end-points were the incidence of allogeneic red cell transfusion and 24-h postoperative blood loss. Data were analyzed according to the intention-to-treat principle and compared using the χ2 and Mann-Whitney U-test. RESULTS: Two-hundred-twenty patients were enrolled (CABG: 134, AVR: 86). In the aprotinin Group 47% of patients received allogeneic blood during the hospital stay as compared to 61% in the tranexamic acid group (P = 0.036). Aprotinin conferred a 23% reduction in allogeneic transfusion risk (RR 0.77, 95% CI 0.53–0.88). Overall, no significant difference in postoperative bleeding was observed, although 24-h blood loss was reduced in aprotinin-treated CABG patients (500, 350–750 mL vs 650, 475–875 mL (median, 25th–75th percentile); P = 0.039). Despite the lower transfusion rate, the hemoglobin concentration on the first postoperative day was higher in the aprotinin group (11.3, 9.9–12.1 vs 10.6, 9.9–11.6 mg/dL; P = 0.023). The fibrinolytic activity at the end of operation determined by D-Dimer was comparable in both groups. (0.15, 0.11–0.17 mg/L [aprotinin] versus 0.18, 0.12–0.24 mg/L [tranexamic acid]). The activated partial thromboplastin time was prolonged up to 4 h postoperatively in the aprotinin group, while the heparin requirement was reduced: 19% of the patients in the aprotinin group and 45% in the tranexamic acid group received at least one additional bolus heparin during cardiopulmonary bypass (P < 0.001). Troponin T levels postoperatively and on postoperative day 1 were significantly higher in the tranexamic acid group (P = 0.017). No differences in renal, cardiac, or mortality outcomes were observed. CONCLUSION: Considering the rate of transfusion of red blood cells, tranexamic acid was slightly inferior in patients undergoing CABG, but there was no difference in patients receiving AVR. Tranexamic acid seems to be less effective in operations with increased bleeding such as CABG. Clinical benefit depends on specific patient and institution characteristics (ClinicalTrials.gov NCT00396760). IMPLICATIONS: In cardiac surgical patients with low risk of bleeding, tranexamic acid was slightly less effective compared to aprotinin in reducing the transfusion incidence." @default.
• W2051884642 created "2016-06-24" @default.
• W2051884642 creator A5004423882 @default.
• W2051884642 creator A5015476149 @default.
• W2051884642 creator A5029660812 @default.
• W2051884642 creator A5057090911 @default.
• W2051884642 creator A5066827407 @default.
• W2051884642 creator A5079020562 @default.
• W2051884642 creator A5086134082 @default.
• W2051884642 date "2008-11-01" @default.
• W2051884642 modified "2023-09-23" @default.
• W2051884642 title "Tranexamic Acid and Aprotinin in Primary Cardiac Operations: An Analysis of 220 Cardiac Surgical Patients Treated with Tranexamic Acid or Aprotinin" @default.
• W2051884642 cites W1967795930 @default.
• W2051884642 cites W1968572199 @default.
• W2051884642 cites W1971495318 @default.
• W2051884642 cites W1978099600 @default.
• W2051884642 cites W1978691495 @default.
• W2051884642 cites W1983199628 @default.
• W2051884642 cites W1986294961 @default.
• W2051884642 cites W1987652595 @default.
• W2051884642 cites W2001747118 @default.
• W2051884642 cites W2003356582 @default.
• W2051884642 cites W2008417338 @default.
• W2051884642 cites W2009699612 @default.
• W2051884642 cites W2011599014 @default.
• W2051884642 cites W2019496208 @default.
• W2051884642 cites W2022022418 @default.
• W2051884642 cites W2023815739 @default.
• W2051884642 cites W2028161433 @default.
• W2051884642 cites W2031311872 @default.
• W2051884642 cites W2036131137 @default.
• W2051884642 cites W2036454015 @default.
• W2051884642 cites W2036468563 @default.
• W2051884642 cites W2044211202 @default.
• W2051884642 cites W2055864845 @default.
• W2051884642 cites W2062839391 @default.
• W2051884642 cites W2063049511 @default.
• W2051884642 cites W2071172794 @default.
• W2051884642 cites W2074349406 @default.
• W2051884642 cites W2096459479 @default.
• W2051884642 cites W2096876696 @default.
• W2051884642 cites W2100390758 @default.
• W2051884642 cites W2109973294 @default.
• W2051884642 cites W2122513836 @default.
• W2051884642 cites W2122523415 @default.
• W2051884642 cites W2123622204 @default.
• W2051884642 cites W2137276105 @default.
• W2051884642 cites W2138768506 @default.
• W2051884642 cites W2146072193 @default.
• W2051884642 cites W2154036079 @default.
• W2051884642 cites W2162606380 @default.
• W2051884642 cites W4232642121 @default.
• W2051884642 cites W4237292819 @default.
• W2051884642 cites W66703609 @default.
• W2051884642 cites W78129447 @default.
• W2051884642 doi "https://doi.org/10.1213/ane.0b013e318182252b" @default.
• W2051884642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18931201" @default.
• W2051884642 hasPublicationYear "2008" @default.
• W2051884642 type Work @default.
• W2051884642 sameAs 2051884642 @default.
• W2051884642 citedByCount "60" @default.
• W2051884642 countsByYear W20518846422012 @default.
• W2051884642 countsByYear W20518846422013 @default.
• W2051884642 countsByYear W20518846422014 @default.
• W2051884642 countsByYear W20518846422015 @default.
• W2051884642 countsByYear W20518846422016 @default.
• W2051884642 countsByYear W20518846422017 @default.
• W2051884642 countsByYear W20518846422018 @default.
• W2051884642 countsByYear W20518846422019 @default.
• W2051884642 countsByYear W20518846422022 @default.
• W2051884642 countsByYear W20518846422023 @default.
• W2051884642 crossrefType "journal-article" @default.
• W2051884642 hasAuthorship W2051884642A5004423882 @default.
• W2051884642 hasAuthorship W2051884642A5015476149 @default.
• W2051884642 hasAuthorship W2051884642A5029660812 @default.
• W2051884642 hasAuthorship W2051884642A5057090911 @default.
• W2051884642 hasAuthorship W2051884642A5066827407 @default.
• W2051884642 hasAuthorship W2051884642A5079020562 @default.
• W2051884642 hasAuthorship W2051884642A5086134082 @default.
• W2051884642 hasConcept C120665830 @default.
• W2051884642 hasConcept C121332964 @default.
• W2051884642 hasConcept C141071460 @default.
• W2051884642 hasConcept C2776820930 @default.
• W2051884642 hasConcept C2778589496 @default.
• W2051884642 hasConcept C2778789114 @default.
• W2051884642 hasConcept C2779637338 @default.
• W2051884642 hasConcept C2780014101 @default.
• W2051884642 hasConcept C2780799893 @default.
• W2051884642 hasConcept C2781436528 @default.
• W2051884642 hasConcept C2991743468 @default.
• W2051884642 hasConcept C42219234 @default.
• W2051884642 hasConcept C61511704 @default.
• W2051884642 hasConcept C71924100 @default.
• W2051884642 hasConceptScore W2051884642C120665830 @default.
• W2051884642 hasConceptScore W2051884642C121332964 @default.
• W2051884642 hasConceptScore W2051884642C141071460 @default.
• W2051884642 hasConceptScore W2051884642C2776820930 @default.
• W2051884642 hasConceptScore W2051884642C2778589496 @default.

• next